NICE Alzheimer’s decision a triumph for scientific reason
This article was originally published in Scrip
Executive Summary
The publication by the UK health technology assessment body NICE (the National Institute for Health and Clinical Excellence) of draft guidance recommending the use of three acetylcholinesterase inhibitors in patients with mild to moderate Alzheimer’s disease, and an NMDA antagonist in patients with more advanced disease, has been widely welcomed as a “courageous decision” and as a “U-turn” on its previous guidance (scripintelligence.com, 7 October 2010).
You may also be interested in...
Thirty-five Years Covering Health Care: The More Things Change…
The health care industry has come a long way in the past 35 years, although in some areas very little has changed. Recently retired In Vivo editor Peter Charlish has seen most of the major developments, and in his final feature, he looks back at some of the big stories in a reporting career that began in the early 1980s.
Transcatheter Systems Set To Dominate Heart Valve Market
Less invasive transcatheter techniques will increasingly displace older, riskier open-heart procedures in the treatment of heart valve disease, according to a new Meddevicetracker report. By 2021, transcatheter systems will account for 76% of the global market for heart valve disease treatment products, with the US retaining its current dominant position in this sector.
Bariatric Devices: Intragastric Balloons To Eclipse Gastric Banding
The market for minimally invasive weight loss devices will reach more than $290 million by 2021, according to a new report from Informa’s Meddevicetracker. Issues relating to laparoscopic adjustable gastric banding systems will result in a greater emphasis being placed on intragastric balloons, which will grow at twice the segment average.